#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic granulomatous disease Myotonic dystrophy Barth syndrome Pulmonary fibrosis Biliary neoplasm Tuberous sclerosis complex Vitamin B12 deficiency Loss of consciousness Lymphoma Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome Systemic lupus erythematosus Hypersomnia Hereditary angioedema Prophylaxis against transplant rejection Brain injury More trials…

    Learn about Rare Diseases

    Atypical haemolytic uraemic syndrome Adrenogenital syndrome – Life with Disease Castleman’s disease – Diagnostics Haemophilia A without inhibitors – Treatment Shprintzen-Goldberg syndrome – Basic Information Sjogren’s syndrome – Trials in Disease Kearns-Sayre syndrome – Trials in Disease Noonan syndrome – Diagnostics Paroxysmal nocturnal haemoglobinuria – Diagnostics Haemophilia B with anti factor IX – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    AUR200 Erythromycin Lactobionate Apl-101 Atuliflapon Regorafenib Tryptophan Fidanacogene Elaparvovec RO7288817 Dimethyl Fumarate Amphotericine B, Liposome Rugonersen Lysine Hydrochloride Anthoxanthum Odoratum Star-0215 Alisertib Sodium Dexchlorpheniramine Maleate Opium, Standardized Powdered Diphenhydramine Hydrochloride Plitidepsin Prs-344 More therapies…

    Learn about Your Condition

    Porphyria non-acute Hypertrophic scar Biliary tract disorder Tuberculosis Lipid metabolism disorder Implantation complication Conjunctivitis Neurogenic bladder Breast cancer stage IV Aplasia pure red cell Toxicity to various agents Autoimmune hepatitis Atrial flutter HIV infection Thrombosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

High-grade B-cell lymphoma

  • Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Loncastuximab Tesirine
    • Epcoritamab
    Germany

  • Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Pegfilgrastim
    • Acalabrutinib
    • Cyclophosphamide
    Germany Greece

  • Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • High-grade B-cell lymphoma
    • Follicular lymphoma
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Loncastuximab Tesirine
    • Epcoritamab
    Germany

  • Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell unclassifiable lymphoma high grade
    • Diffuse large B-cell lymphoma stage I
    • Diffuse large B-cell lymphoma stage II
    Investigated Drugs:
    • Tafasitamab
    • Axicabtagene Ciloleucel
    • Bendamustine Hydrochloride
    Poland

  • Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Primary mediastinal large B-cell lymphoma
    • High-grade B-cell lymphoma
    • Follicular lymphoma
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Fludarabine Phosphate
    • Rapcabtagene Autoleucel
    Austria France Germany Italy Spain

  • Study of Tisagenlecleucel for Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Primary mediastinal large B-cell lymphoma
    • High-grade B-cell lymphoma
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Melphalan
    • Carmustine
    • Bendamustine Hydrochloride
    Austria France Germany Italy The Netherlands Norway +1
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!